company background image
PAB logo

Patrys ASX:PAB Stock Report

Last Price

AU$0.009

Market Cap

AU$18.5m

7D

0%

1Y

-57.1%

Updated

28 Mar, 2024

Data

Company Financials

PAB Stock Overview

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia.

PAB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Patrys Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Patrys
Historical stock prices
Current Share PriceAU$0.009
52 Week HighAU$0.021
52 Week LowAU$0.006
Beta0.36
1 Month Change0%
3 Month Change12.50%
1 Year Change-57.14%
3 Year Change-67.86%
5 Year Change-59.09%
Change since IPO-98.58%

Recent News & Updates

Here's Why It's Unlikely That Patrys Limited's (ASX:PAB) CEO Will See A Pay Rise This Year

Nov 08
Here's Why It's Unlikely That Patrys Limited's (ASX:PAB) CEO Will See A Pay Rise This Year

Recent updates

Here's Why It's Unlikely That Patrys Limited's (ASX:PAB) CEO Will See A Pay Rise This Year

Nov 08
Here's Why It's Unlikely That Patrys Limited's (ASX:PAB) CEO Will See A Pay Rise This Year

Is Patrys (ASX:PAB) In A Good Position To Invest In Growth?

Mar 24
Is Patrys (ASX:PAB) In A Good Position To Invest In Growth?

Here's Why Some Shareholders May Not Be Too Generous With Patrys Limited's (ASX:PAB) CEO Compensation This Year

Nov 09
Here's Why Some Shareholders May Not Be Too Generous With Patrys Limited's (ASX:PAB) CEO Compensation This Year

Will Patrys (ASX:PAB) Spend Its Cash Wisely?

Sep 01
Will Patrys (ASX:PAB) Spend Its Cash Wisely?

Is Patrys (ASX:PAB) In A Good Position To Invest In Growth?

May 11
Is Patrys (ASX:PAB) In A Good Position To Invest In Growth?

We're Not Very Worried About Patrys' (ASX:PAB) Cash Burn Rate

Sep 28
We're Not Very Worried About Patrys' (ASX:PAB) Cash Burn Rate

We're Hopeful That Patrys (ASX:PAB) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Patrys (ASX:PAB) Will Use Its Cash Wisely

Companies Like Patrys (ASX:PAB) Are In A Position To Invest In Growth

Mar 01
Companies Like Patrys (ASX:PAB) Are In A Position To Invest In Growth

What Can We Make Of Patrys' (ASX:PAB) CEO Compensation?

Jan 07
What Can We Make Of Patrys' (ASX:PAB) CEO Compensation?

Shareholder Returns

PABAU BiotechsAU Market
7D0%2.7%1.5%
1Y-57.1%1.4%11.6%

Return vs Industry: PAB underperformed the Australian Biotechs industry which returned 1.4% over the past year.

Return vs Market: PAB underperformed the Australian Market which returned 11.6% over the past year.

Price Volatility

Is PAB's price volatile compared to industry and market?
PAB volatility
PAB Average Weekly Movement16.5%
Biotechs Industry Average Movement11.5%
Market Average Movement8.7%
10% most volatile stocks in AU Market17.1%
10% least volatile stocks in AU Market3.2%

Stable Share Price: PAB has not had significant price volatility in the past 3 months.

Volatility Over Time: PAB's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2006n/aJames Campbellhttps://www.patrys.com

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer.

Patrys Limited Fundamentals Summary

How do Patrys's earnings and revenue compare to its market cap?
PAB fundamental statistics
Market capAU$18.50m
Earnings (TTM)-AU$5.12m
Revenue (TTM)AU$1.70m

10.9x

P/S Ratio

-3.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PAB income statement (TTM)
RevenueAU$1.70m
Cost of RevenueAU$0
Gross ProfitAU$1.70m
Other ExpensesAU$6.82m
Earnings-AU$5.12m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0025
Gross Margin100.00%
Net Profit Margin-302.26%
Debt/Equity Ratio0%

How did PAB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.